OR WAIT null SECS
Increasing complexity of clinical trials targeting cancer—including use of more sophisticated scientific designs, larger global scope, and greater focus on highly targeted patient subpopulations—have intensified the challenges in executing those trials, a newly completed analysis by the Tufts Center for the Study of Drug Development concludes.
From 2000 to 2020, the number of investigational treatments targeting cancer has nearly quadrupled, from 421 to 1,489, according to Tufts CSDD. At the same time, Phase II-III oncology trials, compared to trials for other drugs, makes it more difficult to find, compete for, and enroll patients.
Study results, highlighted in the May/June Tufts CSDD Impact Report, recently released, included the following:
For more information, click here.